1. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. Issue 11 (November 2022) Authors: Bidard, François-Clément; Hardy-Bessard, Anne-Claire; Dalenc, Florence; Bachelot, Thomas; Pierga, Jean-Yves; de la Motte Rouge, Thibault; Sabatier, Renaud; Dubot, Coraline; Frenel, Jean-Sébastien; Ferrero, Jean Marc; Ladoire, Sylvain; Levy, Christelle; Mouret-Reynier, Marie-Ange; Lortholary, Alai... Journal: Lancet oncology Issue: Volume 23:Issue 11(2022) Page Start: 1367 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗